Financials
Financial year 2025
GSK-PROJECTEN from Hasselt, company number BE0890187608, closed financial year 2025 with a result of € 1,748 after tax. For that financial year GSK-PROJECTEN recorded a gross margin of € 12,355 and equity of € 58,618. Compared with financial year 2024, the result moved from € 26,700 to € 1,748. The company is profitable. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on January 30, 2026.
€ 58,618
▲ 3% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 1,748
▼ 93% vs 2024
Profit after tax over the fiscal year.
€ 7,608
▼ 97% vs 2024
Cash and bank balances on the last day of the fiscal year.
Stays in the company
No dividend for 2025. Retained profit grew to € 48,445.
People and assets in 2025
≈ 1
No payroll staff. One director, so that person most likely runs the business.
Debts at end 2025
None
No bank loans on the last day of the fiscal year.
€ 1,671
▼ 82% vs 2024
Supplier invoices still open on the last day of the fiscal year.
€ 5,794
▼ 94% vs 2024
Corporate tax and VAT still to pay. No wage debt: nothing outstanding to staff or social security.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € 42,929 | € 23,237 | € 63,688 | € 12,355 | ▼ 81% |
| Profit after taxes | € 53,649 | € 8,668 | € 26,700 | € 1,748 | ▼ 93% |
| Equity | € 46,501 | € 55,169 | € 56,870 | € 58,618 | ▲ 3% |
| Total debts | € 175,811 | € 330,256 | € 253,656 | € 7,465 | ▼ 97% |
| Cash | € 3,036 | € 4,011 | € 257,216 | € 7,608 | ▼ 97% |
| Land & buildings | - | - | - | € 3,216 | |
| Retained profit | € 27,901 | € 36,569 | € 46,697 | € 48,445 | ▲ 4% |
| Dividend | € 35,000 | € 0 | € 16,573 | € 0 | ▼ 100% |
| Bank debt | € 125,000 | € 231,120 | € 125,000 | € 0 | ▼ 100% |
| Balance sheet total | € 222,312 | € 385,425 | € 310,526 | € 66,083 | ▼ 79% |
Key figures of GSK-PROJECTEN, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 30 January 2027.
What happened to GSK-PROJECTEN?
What happened at GSK-PROJECTEN in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: profit of € 1,748 (▼ 93% vs 2024). Source: NBB ↗
- Gerard Schouten became a director. NBB
- New establishment in Hasselt. KBO
- Start of the company according to the CBE. KBO
In short
From € 53,649 profit in 2022 to € 1,748 profit in 2025.
Paid € 23,680 in corporate taxes since 2022.
Best year ever: 2022, with € 53,649 profit.
Paid out € 51,573 in dividends to the owners in total.
A new publication or filing at GSK-PROJECTEN? We notify you, reason included.
Follow GSK-PROJECTENDatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
The stake of BS Vastgoedmanagement comes from that shareholder’s own annual accounts; small companies do not report their shareholders themselves.
GSK-PROJECTENBehind GSK-PROJECTEN is Gerard Schouten. The shares are held by BS Vastgoedmanagement (50%). It owns 50% of Bouw id itself.
Directors
According to the 2025 annual accounts
since 2024
Shareholders
Participations
50%
Establishments
Establishment units
Physical locations of this company
Guffenslaan 44
3500 Hasselt
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 5 companies are registered at this address.
All companies at this address →What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0890.187.608
- VAT number
- BE 0890.187.608
- Registered office
- Guffenslaan 44, 3500 Hasselt
- Names & denominations
- GSK-PROJECTEN
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 31 May 2007
- Peppol
- Active · Active since 19 Jan 2026
- Activities · NACE
Ontwikkeling van residentiële bouwprojecten
Projectontwikkeling voor woningbouw
Verhuur en exploitatie van eigen of geleased residentieel onroerend goed, exclusief sociale woningen
Verhuur en exploitatie van eigen of geleased niet-residentieel onroerend goed, exclusief terreinen
Ontwikkeling van niet-residentiële bouwprojecten
Activiteiten van adviesbureaus op het gebied van public relations en communicatie
Handel in eigen onroerend goed
Public relationsbureaus
+5